|
1
|
Hazim AZ, Leventakos K and Ernani V:
Evolving field of immunotherapy: Pioneering new paths in Small-cell
lung cancer. JCO Oncol Pract. 21:942–949. 2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yau STY, Hung CT, Leung EYM, Lee A and
Yeoh EK: The interactions among factors associated with the risk of
lung cancer among diabetes patients: A survival tree analysis. NPJ
Prim Care Respir Med. 35(20)2025.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Boloker G, Wang C and Zhang J: Updated
statistics of lung and bronchus cancer in United States (2018). J
Thorac Dis. 10:1158–1161. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sutanto H, Safira A and Fetarayani D: From
tumor to tolerance: A comprehensive review of immune checkpoint
inhibitors and immune-related adverse events. Asia Pac Allergy.
14:124–138. 2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Leach DR, Krummel MF and Allison JP:
Enhancement of antitumor immunity by CTLA-4 blockade. Science.
271:1734–1736. 1996.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ishida Y, Agata Y, Shibahara K and Honjo
T: Induced expression of PD-1, a novel member of the immunoglobulin
gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895.
1992.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Triebel F, Jitsukawa S, Baixeras E,
Roman-Roman S, Genevee C, Viegas-Pequignot E and Hercend T: LAG-3,
a novel lymphocyte activation gene closely related to CD4. J Exp
Med. 171:1393–1405. 1990.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Prasad DV, Richards S, Mai XM and Dong C:
B7S1, a novel B7 family member that negatively regulates T cell
activation. Immunity. 18:863–873. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Monney L, Sabatos CA, Gaglia JL, Ryu A,
Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel
RA, et al: Th1-specific cell surface protein Tim-3 regulates
macrophage activation and severity of an autoimmune disease.
Nature. 415:536–541. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Yu X, Harden K, Gonzalez LC, Francesco M,
Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al: The
surface protein TIGIT suppresses T cell activation by promoting the
generation of mature immunoregulatory dendritic cells. Nat Immunol.
10:48–57. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wherry EJ: T cell exhaustion. Nat Immunol.
12:492–499. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sharma P, Hu-Lieskovan S, Wargo JA and
Ribas A: Primary, adaptive, and acquired resistance to cancer
immunotherapy. Cell. 168:707–723. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hsieh HC, Ling LL and Wang YC:
Post-translational modifications of immune checkpoints: Molecular
mechanisms, tumor microenvironment remodeling, and therapeutic
implications. J Biomed Sci. 33(3)2026.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lu C and Tan Y: Promising immunotherapy
targets: TIM3, LAG3, and TIGIT joined the party. Mol Ther Oncol.
32(200773)2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ye P, Chi X, Cha JH, Luo S, Yang G, Yan X
and Yang WH: Potential of E3 ubiquitin ligases in cancer immunity:
Opportunities and challenges. Cells. 10(3309)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Arkinson C, Dong KC, Gee CL and Martin A:
Mechanisms and regulation of substrate degradation by the 26S
proteasome. Nat Rev Mol Cell Biol. 26:104–122. 2025.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhang Y, Yang J, Min J, Huang S, Li Y and
Liu S: The emerging role of E3 ubiquitin ligases and
deubiquitinases in metabolic dysfunction-associated steatotic liver
disease. J Transl Med. 23(368)2025.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Damgaard RB: The ubiquitin system: From
cell signalling to disease biology and new therapeutic
opportunities. Cell Death Differ. 28:423–426. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Buetow L and Huang DT: Structural insights
into the catalysis and regulation of E3 ubiquitin ligases. Nat Rev
Mol Cell Biol. 17:626–642. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chen X, Zhou J, Dong X, Xu Y and Chen B:
Regulatory role of E3 ubiquitin ligases in multiple myeloma: From
molecular mechanisms to therapeutic strategies. Front Cell Dev
Biol. 13(1620097)2025.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Agrata R and Komander D: Ubiquitin-A
structural perspective. Mol Cell. 85:323–346. 2025.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y,
Lu B, Fan Y, Liu Z, Chen X, et al: Ubiquitination and
deubiquitination in cancer: From mechanisms to novel therapeutic
approaches. Mol Cancer. 23(148)2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Dewson G, Eichhorn PJA and Komander D:
Deubiquitinases in cancer. Nat Rev Cancer. 23:842–862.
2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong
W, Yi M and Xiang B: Regulatory mechanisms of PD-1/PD-L1 in
cancers. Mol Cancer. 23(108)2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Neel BG, Gu H and Pao L: The 'Shp'ing
news: SH2 domain-containing tyrosine phosphatases in cell
signaling. Trends Biochem Sci. 28:284–293. 2003.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sanmamed MF and Chen L: Inducible
expression of B7-H1 (PD-L1) and its selective role in tumor site
immune modulation. Cancer J. 20:256–261. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y,
Liang Y, Guo J, Peng H, Chen M, Fu YX and Tang H: PD-L1 on
dendritic cells attenuates T cell activation and regulates response
to immune checkpoint blockade. Nat Commun. 11(4835)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhang P, Wang Y, Miao Q and Chen Y: The
therapeutic potential of PD-1/PD-L1 pathway on immune-related
diseases: Based on the innate and adaptive immune components.
Biomed Pharmacother. 167(115569)2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Knopf P, Stowbur D, Hoffmann SHL, Hermann
N, Maurer A, Bucher V, Poxleitner M, Tako B, Sonanini D,
Krishnamachary B, et al: Acidosis-mediated increase in
IFN-γ-induced PD-L1 expression on cancer cells as an immune escape
mechanism in solid tumors. Mol Cancer. 22(207)2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhao F, Zhang X, Tang Y, Yang H, Pan H, Li
B, An R, Geyemuri W, Yang C, Wan F and Wu J: Engineered PD-L1
co-expression in PD-1 knockout and MAGE-C2-targeting TCR-T cells
augments the cytotoxic efficacy toward target cancer cells. Sci
Rep. 15(11894)2025.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Strati A, Adamopoulos C, Kotsantis I,
Psyrri A, Lianidou E and Papavassiliou AG: Targeting the PD-1/PD-L1
signaling pathway for cancer therapy: Focus on biomarkers. Int J
Mol Sci. 26(1235)2025.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sun C, Mezzadra R and Schumacher TN:
Regulation and function of the PD-L1 checkpoint. Immunity.
48:434–452. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gao Y, Nihira NT, Bu X, Chu C, Zhang J,
Kolodziejczyk A, Fan Y, Chan NT, Ma L, Liu J, et al:
Acetylation-dependent regulation of PD-L1 nuclear translocation
dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol.
22:1064–1075. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Liu J, Cheng Y, Zheng M, Yuan B, Wang Z,
Li X, Yin J, Ye M and Song Y: Targeting the
ubiquitination/deubiquitination process to regulate immune
checkpoint pathways. Signal Transduct Target Ther.
6(28)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ding L, Chen X, Zhang W, Dai X, Guo H, Pan
X, Xu Y, Feng J, Yuan M, Gao X, et al: Canagliflozin primes
antitumor immunity by triggering PD-L1 degradation in endocytic
recycling. J Clin Invest. 133(e154754)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
De S, Holvey-Bates EG, Mahen K, Willard B
and Stark GR: The ubiquitin E3 ligase FBXO22 degrades PD-L1 and
sensitizes cancer cells to DNA damage. Proc Natl Acad Sci USA.
118:2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang Y, Jia Z, Liang C, He Y, Cong M, Wu
Q, Tian P, He D, Miao X, Sun B, et al: MTSS1 curtails lung
adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1
monoubiquitination and lysosomal degradation. Cell Discov.
9(20)2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Huang G, Kaufman AJ, Ramanathan Y and
Singh B: SCCRO (DCUN1D1) promotes nuclear translocation and
assembly of the neddylation E3 complex. J Biol Chem.
286:10297–10304. 2011.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Li J, Yu T, Yan M, Zhang X, Liao L, Zhu M,
Lin H, Pan H and Yao M: DCUN1D1 facilitates tumor metastasis by
activating FAK signaling and up-regulates PD-L1 in non-small-cell
lung cancer. Exp Cell Res. 374:304–314. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Li J, Xiao X, Ou Y, Cao L, Guo M, Qi C,
Wang Z, Liu Y, Shuai Q, Wang H, et al: USP51/PD-L1/ITGB1-deployed
juxtacrine interaction plays a cell-intrinsic role in promoting
chemoresistant phenotypes in non-small cell lung cancer. Cancer
Commun (Lond). 43:765–787. 2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Guo J, Zhao J, Fu W, Xu Q and Huang D:
Immune evasion and drug resistance mediated by USP22 in cancer:
Novel targets and mechanisms. Front Immunol.
13(918314)2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu
Y, Chang SS, Lin WC, Hsu JM, Hsu YH, et al: Deubiquitination and
stabilization of PD-L1 by CSN5. Cancer Cell. 30:925–939.
2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Ren W, Xu Z, Chang Y, Ju F, Wu H, Liang Z,
Zhao M, Wang N, Lin Y, Xu C, et al: Pharmaceutical targeting of
OTUB2 sensitizes tumors to cytotoxic T cells via degradation of
PD-L1. Nat Commun. 15(9)2024.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Wang S, Iyer R, Han X, Wei J, Li N, Cheng
Y, Zhou Y, Gao Q, Zhang L, Yan M, et al: CRISPR screening
identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator
for tumor immune evasion. J Clin Invest.
133(e167728)2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Mao R, Tan X, Xiao Y, Wang X, Wei Z, Wang
J, Wang X, Zhou H, Zhang L and Shi Y: Ubiquitin C-terminal
hydrolase L1 promotes expression of programmed cell death-ligand 1
in non-small-cell lung cancer cells. Cancer Sci. 111:3174–3183.
2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Pan J, Qiao Y, Chen C, Zang H, Zhang X, Qi
F, Chang C, Yang F, Sun M, Lin S, et al: USP5 facilitates non-small
cell lung cancer progression through stabilization of PD-L1. Cell
Death Dis. 12(1051)2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Wang J, Fang S, Jiang Y and Hua Q:
Unraveling the mechanism of action of Ubiquitin-specific Protease 5
and its inhibitors in tumors. Clin Med Insights Oncol.
18(11795549241281932)2024.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Liang M, Sun Z, Chen X, Wang L, Wang H,
Qin L, Zhao W and Geng B: E3 ligase TRIM28 promotes anti-PD-1
resistance in non-small cell lung cancer by enhancing the
recruitment of myeloid-derived suppressor cells. J Exp Clin Cancer
Res. 42(275)2023.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Tang F, Lu C, He X, Lin W, Xie B, Gao X,
Peng Y, Yang D, Sun L and Weng L: E3 ligase Trim35 inhibits LSD1
demethylase activity through K63-linked ubiquitination and enhances
anti-tumor immunity in NSCLC. Cell Rep. 42(113477)2023.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Liu J, Wei L, Hu N, Wang D, Ni J, Zhang S,
Liu H, Lv T, Yin J, Ye M and Song Y: FBW7-mediated ubiquitination
and destruction of PD-1 protein primes sensitivity to anti-PD-1
immunotherapy in non-small cell lung cancer. J Immunother Cancer.
10(e005116)2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Qin R, Zhao C, Wang CJ, Xu W, Zhao JY, Lin
Y, Yuan YY, Lin PC, Li Y, Zhao S and Huang Y: Tryptophan
potentiates CD8(+) T cells against cancer cells by TRIP12
tryptophanylation and surface PD-1 downregulation. J Immunother
Cancer. 9(e002840)2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Dai X, Lu L, Deng S, Meng J, Wan C, Huang
J, Sun Y, Hu Y, Wu B, Wu G, et al: USP7 targeting modulates
anti-tumor immune response by reprogramming Tumor-associated
macrophages in lung cancer. Theranostics. 10:9332–9347.
2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Yang Z, Xu G, Wang B, Liu Y, Zhang L, Jing
T, Tang M, Xu X, Jiao K, Xiang L, et al: USP12 downregulation
orchestrates a protumourigenic microenvironment and enhances lung
tumour resistance to PD-1 blockade. Nat Commun.
12(4852)2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Jin JO, Puranik N, Bui QT, Yadav D and Lee
PC: The ubiquitin system: An emerging therapeutic target for lung
cancer. Int J Mol Sci. 22(9629)2021.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Parry RV, Chemnitz JM, Frauwirth KA,
Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB
and Riley JL: CTLA-4 and PD-1 receptors inhibit T-cell activation
by distinct mechanisms. Mol Cell Biol. 25:9543–9553.
2005.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Patsoukis N, Bardhan K, Chatterjee P, Sari
D, Liu B, Bell LN, Karoly ED, Freeman GJ, Petkova V, Seth P, et al:
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis
and promoting lipolysis and fatty acid oxidation. Nat Commun.
6(6692)2015.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Ren J, Lv L, Tao X, Zhai X, Chen X, Yu H,
Zhao X, Kong X, Yu Z, Dong D and Liu J: The role of CBL family
ubiquitin ligases in cancer progression and therapeutic strategies.
Front Pharmacol. 15(1432545)2024.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Quan Z, Yang Y, Zheng H, Zhan Y, Luo J,
Ning Y and Fan S: Clinical implications of the interaction between
PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment
of non-small cell lung cancer. J Cancer. 13:3434–3443.
2022.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Dai P, Sun Y, Huang Z, Liu YT, Gao M, Liu
HM, Shi J, He C, Xiang B, Yao Y, et al: USP2 inhibition unleashes
CD47-restrained phagocytosis and enhances anti-tumor immunity. Nat
Commun. 16(4564)2025.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Xiong W, Gao X, Zhang T, Jiang B, Hu MM,
Bu X, Gao Y, Zhang LZ, Xiao BL, He C, et al: USP8 inhibition
reshapes an inflamed tumor microenvironment that potentiates the
immunotherapy. Nat Commun. 13(1700)2022.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Wang S, Xu L, Che X, Li C, Xu L, Hou K,
Fan Y, Wen T, Qu X and Liu Y: E3 ubiquitin ligases Cbl-b and c-Cbl
downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
FEBS Lett. 592:621–630. 2018.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Zeng X, Tang X, Chen X and Wen H: RNF182
induces p65 ubiquitination to affect PDL1 transcription and
suppress immune evasion in lung adenocarcinoma. Immun Inflamm Dis.
11(e864)2023.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Sun D, Duan X, Li N, Qiao O, Hou Y, Ma Z,
Liu S, Gong Y and Liu Z: Construction of ubiquitination-related
risk model for predicting prognosis in lung adenocarcinoma. Sci
Rep. 15(11787)2025.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Aggarwal V, Workman CJ and Vignali DAA:
LAG-3 as the third checkpoint inhibitor. Nat Immunol. 24:1415–1422.
2023.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Maçon-Lemaître L and Triebel F: The
negative regulatory function of the lymphocyte-activation gene-3
co-receptor (CD223) on human T cells. Immunology. 115:170–178.
2005.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Blackburn SD, Shin H, Haining WN, Zou T,
Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA and Wherry
EJ: Coregulation of CD8+ T cell exhaustion by multiple inhibitory
receptors during chronic viral infection. Nat Immunol. 10:29–37.
2009.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Chocarro L, Blanco E, Zuazo M, Arasanz H,
Bocanegra A, Fernández-Rubio L, Morente P, Fernández-Hinojal G,
Echaide M, Garnica M, et al: Understanding LAG-3 Signaling. Int J
Mol Sci. 22(5282)2021.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Hannier S, Tournier M, Bismuth G and
Triebel F: CD3/TCR complex-associated lymphocyte activation gene-3
molecules inhibit CD3/TCR signaling. J Immunol. 161:4058–4065.
1998.PubMed/NCBI
|
|
71
|
Ming Q, Antfolk D, Price DA, Manturova A,
Medina E, Singh S, Mason C, Tran TH, Smalley KSM, Leung DW and Luca
VC: Structural basis for mouse LAG3 interactions with the MHC class
II molecule I-Ab. Nat Commun. 15(7513)2024.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Hemon P, Jean-Louis F, Ramgolam K,
Brignone C, Viguier M, Bachelez H, Triebel F, Charron D, Aoudjit F,
Al-Daccak R and Michel L: MHC class II engagement by its ligand
LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J
Immunol. 186:5173–5183. 2011.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Donia M, Andersen R, Kjeldsen JW, Fagone
P, Munir S, Nicoletti F, Andersen MH, Thor Straten P and Svane IM:
Aberrant expression of MHC class II in melanoma attracts
inflammatory Tumor-specific CD4+ T-cells, which dampen CD8+ T-cell
antitumor reactivity. Cancer Res. 75:3747–3759. 2015.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Merenstein A, Obeidat L, Zaravinos A and
Bonavida B: The role of YY1 in the regulation of LAG-3 expression
in CD8 T cells and immune evasion in cancer: Therapeutic
implications. Cancers (Basel). 17(19)2024.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Kouo T, Huang L, Pucsek AB, Cao M, Solt S,
Armstrong T and Jaffee E: Galectin-3 shapes antitumor immune
responses by suppressing CD8+ T cells via LAG-3 and inhibiting
expansion of plasmacytoid dendritic cells. Cancer Immunol Res.
3:412–423. 2015.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Personnaz J, Guillou H and Kautz L:
Fibrinogen-like 1: A hepatokine linking liver physiology to
hematology. Hemasphere. 8(e115)2024.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Yu J, Li J, Shen J, Du F, Wu X, Li M, Chen
Y, Cho CH, Li X, Xiao Z and Zhao Y: The role of Fibrinogen-like
proteins in cancer. Int J Biol Sci. 17:1079–1087. 2021.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Nayeb-Hashemi H, Desai A, Demchev V,
Bronson RT, Hornick JL, Cohen DE and Ukomadu C: Targeted disruption
of fibrinogen like protein-1 accelerates hepatocellular carcinoma
development. Biochem Biophys Res Commun. 465:167–173.
2015.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Liu TY, Yan JS, Li X, Xu L, Hao JL, Zhao
SY, Hu QL, Na FJ, Li HM, Zhao Y and Zhao MF: FGL1: A novel
biomarker and target for non-small cell lung cancer, promoting
tumor progression and metastasis through KDM4A/STAT3 transcription
mechanism. J Exp Clin Cancer Res. 43(213)2024.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Andrews LP, Somasundaram A, Moskovitz JM,
Szymczak-Workman AL, Liu C, Cillo AR, Lin H, Normolle DP, Moynihan
KD, Taniuchi I, et al: Resistance to PD1 blockade in the absence of
metalloprotease-mediated LAG3 shedding. Sci Immunol.
5(eabc2728)2020.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Kim JY, Kim J, Cho EY, Park YH, Ahn JS,
Kim KM and Im YH: Lymphocyte-activating gene 3 expression in tumor
cells predicts immune checkpoint inhibitor response in triple
negative breast cancer. Front Oncol. 13(1146934)2023.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Tsygankov AY, Teckchandani AM, Feshchenko
EA and Swaminathan G: Beyond the RING: CBL proteins as multivalent
adapters. Oncogene. 20:6382–6402. 2001.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Meng W, Sawasdikosol S, Burakoff SJ and
Eck MJ: Structure of the amino-terminal domain of Cbl complexed to
its binding site on ZAP-70 kinase. Nature. 398:84–90.
1999.PubMed/NCBI View
Article : Google Scholar
|
|
84
|
Jiang Y, Dai A, Huang Y, Li H, Cui J, Yang
H, Si L, Jiao T, Ren Z, Zhang Z, et al: Ligand-induced
ubiquitination unleashes LAG3 immune checkpoint function by
hindering membrane sequestration of signaling motifs. Cell.
188:2354–2371.e18. 2025.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Tian T, Xie X, Yi W, Zhou Y, Xu Y, Wang Z,
Zhang J, Lin M, Zhang R, Lv Z, et al: FBXO38 mediates FGL1
ubiquitination and degradation to enhance cancer immunity and
suppress inflammation. Cell Rep. 42(113362)2023.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Wescott EC, Sun X, Gonzalez-Ericsson P,
Hanna A, Taylor BC, Sanchez V, Bronzini J, Opalenik SR, Sanders ME,
Wulfkuhle J, et al: Epithelial expressed B7-H4 drives differential
immunotherapy response in murine and human breast cancer. Cancer
Res Commun. 4:1120–1134. 2024.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Zang X, Loke P, Kim J, Murphy K, Waitz R
and Allison JP: B7x: A widely expressed B7 family member that
inhibits T cell activation. Proc Natl Acad Sci USA.
100:10388–10392. 2003.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Sun Y, Wang Y, Zhao J, Gu M, Giscombe R,
Lefvert AK and Wang X: B7-H3 and B7-H4 expression in non-small-cell
lung cancer. Lung Cancer. 53:143–151. 2006.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Qi Y, Hu L, Ji C, Yang X, Yao J, Chen D
and Yao Y: B7-H4 reduces the infiltration of CD8+T cells and
induces their anti-tumor dysfunction in gliomas. Neoplasia.
54(101007)2024.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Wang JY and Wang WP: B7-H4, a promising
target for immunotherapy. Cell Immunol. 347(104008)2020.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Lu Y, Sun Y, Zhang J, Kong M, Zhao Z, Sun
B, Wang Y, Jiang Y, Chen S, Wang C, et al: The deubiquitinase USP2a
promotes tumor immunosuppression by stabilizing immune checkpoint
B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.
Cancer Lett. 596(217020)2024.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
Squamous-cell Non-Small-cell lung cancer. N Engl J Med.
373:123–135. 2015.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-Positive
Non-small-cell lung cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Johnson ML, Cho BC, Luft A,
Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G,
Hussein M, Lim FL, et al: Durvalumab with or without tremelimumab
in combination with chemotherapy as First-Line therapy for
metastatic Non-Small-Cell lung cancer: The phase III POSEIDON
study. J Clin Oncol. 41:1213–1227. 2023.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Haslam A and Prasad V: Estimation of the
percentage of US patients with cancer who are eligible for and
respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw
Open. 2(e192535)2019.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Liu Y, Liu X, Zhang N, Yin M, Dong J, Zeng
Q, Mao G, Song D, Liu L and Deng H: Berberine diminishes cancer
cell PD-L1 expression and facilitates antitumor immunity via
inhibiting the deubiquitination activity of CSN5. Acta Pharm Sin B.
10:2299–2312. 2020.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Lingaraju GM, Bunker RD, Cavadini S, Hess
D, Hassiepen U, Renatus M, Fischer ES and Thomä NH: Crystal
structure of the human COP9 signalosome. Nature. 512:161–165.
2014.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Hung MS, Chen IC, You L, Jablons DM, Li
YC, Mao JH, Xu Z, Lung JH, Yang CT and Liu ST: Knockdown of cullin
4A inhibits growth and increases chemosensitivity in lung cancer
cells. J Cell Mol Med. 20:1295–1306. 2016.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Lin CY, Huang KY, Kao SH, Lin MS, Lin CC,
Yang SC, Chung WC, Chang YH, Chein RJ and Yang PC: Small-molecule
PIK-93 modulates the tumor microenvironment to improve immune
checkpoint blockade response. Sci Adv. 9(eade9944)2023.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Kirtonia A, Gala K, Fernandes SG, Pandya
G, Pandey AK, Sethi G, Khattar E and Garg M: Repurposing of drugs:
An attractive pharmacological strategy for cancer therapeutics.
Semin Cancer Biol. 68:258–278. 2021.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Wang Z, Lu C, Zhang K, Lin C, Wu F, Tang
X, Wu D, Dou Y, Han R, Wang Y, et al: Metformin Combining PD-1
inhibitor enhanced Anti-tumor efficacy in STK11 mutant lung cancer
through AXIN-1-dependent inhibition of STING ubiquitination. Front
Mol Biosci. 9(780200)2022.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo
CW, Khoo KH, Chang SS, Cha JH, Kim T, et al: Glycosylation and
stabilization of programmed death ligand-1 suppresses T-cell
activity. Nat Commun. 7(12632)2016.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Wang M, Guo H, Sun BB, Jie XL, Shi XY, Liu
YQ, Shi XL, Ding LQ, Xue PH, Qiu F, et al: Centipeda minima and
6-O-angeloylplenolin enhance the efficacy of immune checkpoint
inhibitors in non-small cell lung cancer. Phytomedicine.
132(155825)2024.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Hong Z, Liu F and Zhang Z: Ubiquitin
modification in the regulation of tumor immunotherapy resistance
mechanisms and potential therapeutic targets. Exp Hematol Oncol.
13(91)2024.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Liu X, Cen X, Wu R, Chen Z, Xie Y, Wang F,
Shan B, Zeng L, Zhou J, Xie B, et al: ARIH1 activates
STING-mediated T-cell activation and sensitizes tumors to immune
checkpoint blockade. Nat Commun. 14(4066)2023.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Lippert TP and Greenberg RA: The abscopal
effect: A sense of DNA damage is in the air. J Clin Invest.
131(e148274)2021.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Chirnomas D, Hornberger KR and Crews CM:
Protein degraders enter the clinic-a new approach to cancer
therapy. Nat Rev Clin Oncol. 20:265–278. 2023.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Antao AM, Tyagi A, Kim KS and Ramakrishna
S: Advances in deubiquitinating enzyme inhibition and applications
in cancer therapeutics. Cancers (Basel). 12(1579)2020.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C,
Chen Y, Fan L, Ma H, Gong Y and Xie Y: An overview of PROTACs: A
promising drug discovery paradigm. Mol Biomed. 3(46)2022.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Hsu SK, Chou CK, Lin IL, Chang WT, Kuo IY
and Chiu CC: Deubiquitinating enzymes: Potential regulators of the
tumor microenvironment and implications for immune evasion. Cell
Commun Signal. 22(259)2024.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Sajjad H, Imtiaz S, Noor T, Siddiqui YH,
Sajjad A and Zia M: Cancer models in preclinical research: A
chronicle review of advancement in effective cancer research.
Animal Model Exp Med. 4:87–103. 2021.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Proietto M, Crippa M, Damiani C, Pasquale
V, Sacco E, Vanoni M and Gilardi M: Tumor heterogeneity:
Preclinical models, emerging technologies, and future applications.
Front Oncol. 13(1164535)2023.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Dar AA: Editorial: Ubiquitination in tumor
pathogenesis and progression and its therapeutic potential. Front
Immunol. 17(1786943)2026.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Ding P, Ma Z, Fan Y, Feng Y, Shao C, Pan
M, Zhang Y, Huang D, Han J, Hu Y and Yan X: Emerging role of
ubiquitination/deubiquitination modification of PD-1/PD-L1 in
cancer immunotherapy. Genes Dis. 10:848–863. 2023.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Zhang H, Yan H, Liu Y, Zeng A and Song L:
The ubiquitination-autophagy axis in cancer therapy resistance:
Mechanistic insights and therapeutic opportunities. Front
Pharmacol. 16(1722559)2025.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Su Y, Wang Y, Liu F and Chen Q: Pan-cancer
multi-omics profiling reveals ubiquitin D as a novel biomarker for
diagnosis, immune microenvironment remodeling and prognostic
prediction. Discov Oncol. 16(1707)2025.PubMed/NCBI View Article : Google Scholar
|
